Mr Doug Brough | Chief Scientific Officer
Genvec

Doug Brough joined GenVec in 1993 and serves as Chief Scientific Officer of the Company, having previously held several senior positions in GenVec Research. Dr. Brough was directly involved in the discovery of our core adenovirus vector technology and proprietary production cell lines with demonstrated scale-up and production viability. He led GenVec’s hearing and balance program, which is currently partnered for clinical testing and commercial development with Novartis; as well as the research efforts for the first adenovector-based Foot and Mouth Disease vaccine to be approved by the USDA as part of a collaboration between GenVec, the Agricultural Research Service of the USDA, and the Department of Homeland Security. Dr. Brough received his B.S. in Biology from Purdue University, his M.S. in Microbiology and Biochemistry from Idaho State University, and his Ph.D. in Microbiology and Molecular Genetics from Rutgers, the State University of New Jersey and the Robert Wood Johnson Medical School.